Companies: 10,795·Total market cap: $144.5T
Tharimmune, Inc.

Tharimmune, Inc.

THARNASDAQHealthcare
$3.54
+$0.22(+6.63%)
Market Cap$139935658
P/E Ratio
52W High$9.08
52W Low$0.952
Overview

Tharimmune, Inc.(THAR)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · THAR · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-2.00thar eps ttm · thar earnings per shareEarnings history
PE Ratio (TTM)thar pe ratio ttm · thar price to earningsPE Ratio deep dive
Revenue (TTM)0.00thar revenue ttm · thar annual revenueFull revenue history
Dividend Yield不分红does thar pay dividends · thar dividend yieldDividend history
Shares Outstanding32.0Mthar shares outstanding · thar floatShares outstanding history
Next EarningsTBAthar earnings date · thar next earningsEarnings history

财务快照

完整财报
FY 2025Revenue$0.00
202320242025
tharimmune, inc. revenue · thar revenue 2025
FY 2025Net Income-$35.9M▼ 194.45% YoY
202320242025
tharimmune, inc. net income · thar profit 2025
FY 2025EPS$-1.12▲ +88.10% YoY
202320242025
thar eps · tharimmune, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$80.7MEPS: $-2.00View income statement →

分析师评级与目标价

完整预测
SellBuy
Hold1 位分析师is thar a buy · thar analyst rating
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$Low
$3.54Current
$Avg Target
$High
thar price target · thar 12 month forecast

合计: 1 · 买入占比: 0.0%

股票表现

完整历史
1D+0.00%
1W-1.67%
1M-0.28%
3M-24.36%
YTD+16.83%
1Y+158.39%
5Y-99.73%

关于 Tharimmune, Inc.

CEOMark Wendland
IPO DateJan 12, 2022
Employees2
CountryUS

Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology …

what is tharimmune, inc. · thar stock overview · tharimmune, inc. company profile · who is tharimmune, inc. ceo · thar NASDAQ · tharimmune, inc. headquarters · tharimmune, inc. business segments

关于股票概览与关键数据

Tharimmune, Inc.(THAR)是 Biotechnology 行业的 Healthcare 类公司,于 Jan 12, 2022 在 NASDAQ 上市。截至最近交易日,THAR 股价为 $3.54,市值约为 $139.9M。过去12个月累计回报 +158.39%,年初至今回报 +16.83%。

根据 1 位华尔街分析师,Tharimmune, Inc. 股票共识评级为Hold,12个月平均目标价为 $—。2025 财年 Tharimmune, Inc. 营收 —,净利润 -$35.9M。更多数据(营收历史、盈利、股息、市盈率)请使用上方标签页。

常见问题

截至最近一个交易日,Tharimmune, Inc.(THAR)股价为 $3.54,在 NASDAQ 上市,52周区间为 $0.95 – $9.08。

THAR 最新股价THAR quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 8, 2026本内容不构成投资建议